ATE281169T1 - Beta-l-dioxolanuridin-analoge zur behandlung und vorbeugung von durch ebv, vzv bzw. hv-8 verursachten viralen infektionen - Google Patents

Beta-l-dioxolanuridin-analoge zur behandlung und vorbeugung von durch ebv, vzv bzw. hv-8 verursachten viralen infektionen

Info

Publication number
ATE281169T1
ATE281169T1 AT97947480T AT97947480T ATE281169T1 AT E281169 T1 ATE281169 T1 AT E281169T1 AT 97947480 T AT97947480 T AT 97947480T AT 97947480 T AT97947480 T AT 97947480T AT E281169 T1 ATE281169 T1 AT E281169T1
Authority
AT
Austria
Prior art keywords
vzv
ebv
virus
beta
dioxolanuridine
Prior art date
Application number
AT97947480T
Other languages
English (en)
Inventor
Yung-Chi Cheng
Chung K Chu
Fucheng Qu
Original Assignee
Univ Yale
Univ Georgia Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/749,263 external-priority patent/US5792773A/en
Application filed by Univ Yale, Univ Georgia Res Found filed Critical Univ Yale
Application granted granted Critical
Publication of ATE281169T1 publication Critical patent/ATE281169T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT97947480T 1996-11-15 1997-11-14 Beta-l-dioxolanuridin-analoge zur behandlung und vorbeugung von durch ebv, vzv bzw. hv-8 verursachten viralen infektionen ATE281169T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/749,263 US5792773A (en) 1996-11-15 1996-11-15 L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US08/954,922 US6022876A (en) 1996-11-15 1997-10-21 L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
PCT/US1997/020647 WO1998020879A1 (en) 1996-11-15 1997-11-14 L-β-DIOXOLANE URIDINE ANALOGS AND METHODS FOR TREATING AND PREVENTING VIRUS INFECTIONS

Publications (1)

Publication Number Publication Date
ATE281169T1 true ATE281169T1 (de) 2004-11-15

Family

ID=27115085

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97947480T ATE281169T1 (de) 1996-11-15 1997-11-14 Beta-l-dioxolanuridin-analoge zur behandlung und vorbeugung von durch ebv, vzv bzw. hv-8 verursachten viralen infektionen

Country Status (11)

Country Link
US (3) US6022876A (de)
EP (1) EP0956021B1 (de)
JP (1) JP2001504468A (de)
KR (1) KR20000069003A (de)
CN (1) CN1244799A (de)
AT (1) ATE281169T1 (de)
AU (1) AU737209C (de)
BR (1) BR9713074A (de)
CA (1) CA2272404A1 (de)
DE (1) DE69731483T2 (de)
WO (1) WO1998020879A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
CA2385349A1 (en) * 1999-09-24 2001-04-05 Francis J. Giles Method for the treatment or prevention of viral infection using nucleoside analogues
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
CA2470938A1 (en) 2001-12-20 2003-07-03 Beth Israel Deaconess Medical Center Treatment of ebv and khsv infection and associated abnormal cellular proliferation
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
NZ729118A (en) 2014-08-25 2022-02-25 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer
EP4423100A4 (de) * 2021-10-29 2025-04-23 University of Georgia Research Foundation, Inc. Prodrugs von l-bhdu und verfahren zur behandlung von virusinfektionen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections

Also Published As

Publication number Publication date
JP2001504468A (ja) 2001-04-03
US20010018440A1 (en) 2001-08-30
BR9713074A (pt) 2002-01-02
DE69731483D1 (de) 2004-12-09
KR20000069003A (ko) 2000-11-25
US6022876A (en) 2000-02-08
CA2272404A1 (en) 1998-05-22
US6274589B1 (en) 2001-08-14
EP0956021B1 (de) 2004-11-03
EP0956021A4 (de) 2000-06-28
DE69731483T2 (de) 2005-10-27
WO1998020879A1 (en) 1998-05-22
AU737209B2 (en) 2001-08-09
CN1244799A (zh) 2000-02-16
EP0956021A1 (de) 1999-11-17
AU5254998A (en) 1998-06-03
AU737209C (en) 2002-03-14

Similar Documents

Publication Publication Date Title
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
AU644095B2 (en) Antiviral compounds
ATE281169T1 (de) Beta-l-dioxolanuridin-analoge zur behandlung und vorbeugung von durch ebv, vzv bzw. hv-8 verursachten viralen infektionen
DK0741577T3 (da) Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren
ATE219366T1 (de) Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
UA29429C2 (uk) Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини
CA2293470A1 (en) Benzimidazole derivatives
DE60022380D1 (de) Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin-phosphorylase-hemmer zur behandlung von hiv
ES2109260T3 (es) Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas.
ATE150317T1 (de) Synergische mischung zur behandlung von herpes
MX9805441A (es) Compuestos terapeuticos.
ATE253368T1 (de) Verwendung von bisphosphonaten zur prophylaxe und zur behandlung von infektiösen prozessen
IE893991L (en) 2',3'-dideoxypurine nucleoside/purine nucleoside¹phosphorylase inhibitor combination therapy and composition
ATE213231T1 (de) Michellamine zur verwendung als antivirale wirkstoffe, zusammensetzung und behandlungsverfahren
BR9916046A (pt) Composto, composição farmacêutica, e, processos para inibir a replicação de um vìrus herpes e para tratamento de um paciente que sofra de uma infecção do vìrus herpes
ATE269081T1 (de) Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
ATE306929T1 (de) Inositolphosphoglycan und ribose zur behandlung von ischämischen-reperfusionschaden
ATE196424T1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
DE69915852D1 (de) Lhrh-analoga zur behandlung der osteoporose
GR960300005T1 (en) Extracts of piliostigma thonningii, the use thereof and formulations containing them.
KR920019362A (ko) 디데옥시 아데노신 및 아데노신 데아미나제 억제물질을 포함하는, 항-hiv활성을 지닌 치료학적 조성물
AU630249B2 (en) Prevention of glycoprotein enveloped virus infectivity by quinolyloxazole-2-ones
TW217986B (en) Compositions for the treatment of infection and disease caused by HBV

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties